In 2019, a small team of researchers reported something new in aging biology: people with a fatal lung disease had taken a senolytic drug combination, and some of them walked farther, moved faster and stood up from a chair more quickly afterward. The paper in EBioMedicine (Justice et al., PMID 30616998) is the first-in-human report of dasatinib plus quercetin (DQ). It is also easy to over-read. This article walks through what was done, what changed, and why the study is a feasibility signal rather than a recipe.
What Are Senolytics?
Cellular senescence is a state in which cells stop dividing but don't die. These cells accumulate with age and in several chronic diseases. They secrete a mix of inflammatory cytokines, matrix-remodeling enzymes and other factors collectively called the senescence-associated secretory phenotype (SASP). The SASP is thought to damage surrounding tissue and keep the inflammatory signal going.
Senolytics are compounds meant to selectively eliminate senescent cells. Idiopathic pulmonary fibrosis (IPF), a progressive scarring disease of the lungs, is a logical target because it is strongly associated with senescence. In the source paper's background, DQ had already been shown to alleviate IPF-related dysfunction in mice given bleomycin, a standard lung-injury model. This pilot was the first test of whether the approach could even be run in people.
The Exact Protocol
The study was a two-center, open-label trial of 14 adults with stable IPF. The mean age was about 70.8, and most participants were men. The regimen was intermittent:
- Dasatinib: 100 mg/day
- Quercetin: 1,250 mg/day
- Schedule: three days per week for three weeks
The intermittent design reflects the "hit-and-run" logic of senolytics. The aim is to clear senescent cells briefly rather than suppress a pathway continuously. The primary endpoints were not efficacy. They were retention and completion of planned clinical assessments. Safety and changes in function and reported health were secondary endpoints.
What the Results Showed
On feasibility, the pilot did well. Retention was 100%, no one discontinued DQ, and planned assessments were completed in 13 of 14 participants.
On physical function, the authors reported significant, clinically meaningful improvements (p < .05) in three measures:
- 6-minute walk distance
- 4-meter gait speed
- Chair-stands time
Other measures did not move. Pulmonary function, clinical chemistries, the frailty index (FI-LAB) and self-reported health were unchanged. That matters. The lungs' measured performance did not improve, so the functional gains cannot be read as reversed fibrosis.
The biomarker findings were exploratory. DQ's effects on circulating SASP factors were inconclusive. The authors did observe correlations between changes in function and changes in SASP-related matrix-remodeling proteins, microRNAs and pro-inflammatory cytokines (23 of 48 markers had r ≥ 0.50). In a 14-person study without a control group, these correlations are hypothesis-generating at best.
The Safety Signal
One serious adverse event was reported. Non-serious events were mostly mild to moderate. The most frequent were:
- Respiratory symptoms (16 events in total)
- Skin irritation or bruising (14 events)
- Gastrointestinal discomfort (12 events)
Dasatinib is a tyrosine kinase inhibitor used in oncology, and it carries real risks. A short course in a monitored trial with clinical oversight is very different from unsupervised use. Respiratory symptoms were also the most common event category in a population that already has lung disease. That deserves attention in any larger trial.
The Clear Flag: This Is Not a Supplement Stack
The study's popularity in longevity circles invites a misreading, so the limits need to be stated plainly.
- It's a drug plus a pharmacologic flavonoid dose. Dasatinib is a prescription cancer medication. The 1,250 mg/day quercetin dose used here is a trial-specified dose given with the drug, not a general endorsement of over-the-counter quercetin products.
- It was open-label and uncontrolled. Participants and investigators knew everyone was receiving DQ. There was no placebo arm. Walking speed, chair-stand time and 6-minute walk distance are effort-dependent, so expectation, learning effects and motivation can all contribute.
- The sample was tiny. Fourteen people with stable IPF, mostly older men, is a feasibility cohort. It cannot establish efficacy or rule out rarer harms.
- The course was short. Three weeks of intermittent dosing says little about durability or long-term safety.
- The population was specific. The findings concern IPF. They don't automatically transfer to healthy older adults or to other conditions.
The authors themselves frame the result accordingly: the pilot "supports study feasibility" and gives "initial evidence" that senolytics may alleviate physical dysfunction, warranting evaluation in larger randomized controlled trials.
Research-Literacy Takeaways
Rather than treating this as a protocol to copy, use it as a case study in reading early-phase trials.
- Check the primary endpoint. This trial was designed to answer "can we run this?" and it largely did. The functional improvements were secondary outcomes.
- Look for the control group. Without placebo and blinding, subjective or effort-based measures are vulnerable to bias.
- Count the comparisons. Many outcomes in 14 people raise the odds that some p-values fall below .05 by chance. Replication matters more than any single p-value.
- Note what didn't change. Unchanged lung function, labs and frailty index temper any story about disease modification.
- Separate mechanism from outcome. The SASP results were inconclusive. The study doesn't demonstrate that senescent cells were cleared or that clearance caused the functional gains.
- Match the population to the claim. Evidence in patients with IPF, on a supervised regimen, is not evidence for a consumer product.
What Comes Next
The value of this paper is that it moved senolytics from mouse models into humans and showed that a structured, intermittent protocol could be delivered and tolerated well enough to complete in a small group. That is the necessary first step, and the registered trial (NCT02874989) gives the work a transparent record. The real test will be randomized, blinded, adequately powered studies with predefined primary outcomes and stronger biomarker readouts. Until those exist, the fair summary is a promising signal with large unanswered questions.
